126 related articles for article (PubMed ID: 10386467)
1. Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics, and endocrine and clinical effects, of a parenteral estrogen regimen.
Henriksson P; Carlström K; Pousette A; Gunnarsson PO; Johansson CJ; Eriksson B; Altersgård-Brorsson AK; Nordle O; Stege R
Prostate; 1999 Jul; 40(2):76-82. PubMed ID: 10386467
[TBL] [Abstract][Full Text] [Related]
2. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study.
Hedlund PO; Henriksson P
Urology; 2000 Mar; 55(3):328-33. PubMed ID: 10699602
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic model of testosterone suppression after intramuscular depot estrogen therapy in prostate cancer.
Johansson CJ; Gunnarsson PO
Prostate; 2000 Jun; 44(1):26-30. PubMed ID: 10861754
[TBL] [Abstract][Full Text] [Related]
4. Adrenocortical function in prostatic cancer patients: effects of orchidectomy or different modes of estrogen treatment on basal steroid levels and on the response to exogenous adrenocorticotropic hormone.
Carlström K; Stege R
Urol Int; 1990; 45(3):160-3. PubMed ID: 2161578
[TBL] [Abstract][Full Text] [Related]
5. Single-drug parenteral estrogen treatment in prostatic cancer: a study of two maintenance-dose regimens.
Stege R; Carlström K; Collste L; Eriksson A; Henriksson P; Pousette A; von Schoultz B
Prostate; 1989; 14(2):183-8. PubMed ID: 2710692
[TBL] [Abstract][Full Text] [Related]
6. Possible bone-preserving capacity of high-dose intramuscular depot estrogen as compared to orchidectomy in the treatment of patients with prostatic carcinoma.
Carlström K; Stege R; Henriksson P; Grande M; Gunnarsson PO; Pousette A
Prostate; 1997 May; 31(3):193-7. PubMed ID: 9167772
[TBL] [Abstract][Full Text] [Related]
7. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
Hedlund PO; Ala-Opas M; Brekkan E; Damber JE; Damber L; Hagerman I; Haukaas S; Henriksson P; Iversen P; Pousette A; Rasmussen F; Salo J; Vaage S; Varenhorst E;
Scand J Urol Nephrol; 2002; 36(6):405-13. PubMed ID: 12623503
[TBL] [Abstract][Full Text] [Related]
8. Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group.
Mikkola AK; Ruutu ML; Aro JL; Rannikko SA; Salo JO
Br J Urol; 1998 Jul; 82(1):63-8. PubMed ID: 9698663
[TBL] [Abstract][Full Text] [Related]
9. Plasma concentrations of estradiol and testosterone in single-drug polyestradiol phosphate therapy for prostatic cancer.
Norlén BJ; Fritjofsson A; Grönquist L; Gunnarsson PO; Johansson SA; Plym-Forshell G
Eur Urol; 1987; 13(3):193-7. PubMed ID: 3609099
[TBL] [Abstract][Full Text] [Related]
10. Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in males.
Berglund L; Carlström K; Stege R; Gottlieb C; Eriksson M; Angelin B; Henriksson P
J Clin Endocrinol Metab; 1996 Jul; 81(7):2633-7. PubMed ID: 8675589
[TBL] [Abstract][Full Text] [Related]
11. Effects of orchidectomy and different modes of high dose estrogen treatment on circulating "free" and total 1,25-dihydroxyvitamin D in patients with prostatic cancer.
Hagenfeldt Y; Carlström K; Berlin T; Stege R
J Steroid Biochem Mol Biol; 1991 Aug; 39(2):155-9. PubMed ID: 1888674
[TBL] [Abstract][Full Text] [Related]
12. Single drug polyestradiol phosphate therapy in prostatic cancer.
Stege R; Carlström K; Collste L; Eriksson A; Henriksson P; Pousette A
Am J Clin Oncol; 1988; 11 Suppl 2():S101-3. PubMed ID: 3242384
[TBL] [Abstract][Full Text] [Related]
13. [Endocrine treatment of prostatic cancer. A renaissance for parenteral estrogen].
Stege R; Sander S
Tidsskr Nor Laegeforen; 1993 Mar; 113(7):833-5. PubMed ID: 8480286
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate.
Henriksson P; Eriksson A; Stege R; Collste L; Pousette A; von Schoultz B; Carlström K
Prostate; 1988; 13(3):257-61. PubMed ID: 3211807
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population.
Aro J
Prostate; 1991; 18(2):131-7. PubMed ID: 2006119
[TBL] [Abstract][Full Text] [Related]
16. Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy.
Mikkola A; Aro J; Rannikko S; Ruutu M;
Prostate; 2007 Mar; 67(4):447-55. PubMed ID: 17219379
[TBL] [Abstract][Full Text] [Related]
17. Effects of orchiectomy and polyestradiol phosphate therapy on serum lipoprotein lipids and glucose tolerance in prostatic cancer patients.
Aro J; Haapiainen R; Sane T; Rannikko S; Pelkonen R; Alfthan O
Eur Urol; 1990; 17(3):229-35. PubMed ID: 2351192
[TBL] [Abstract][Full Text] [Related]
18. The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium.
Mikkola A; Ruutu M; Aro J; Rannikko S; Salo J
Ann Chir Gynaecol; 1999; 88(1):18-21. PubMed ID: 10230677
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin) in prostatic cancer patients.
Stege R; Gunnarsson PO; Johansson CJ; Olsson P; Pousette A; Carlström K
Prostate; 1996 May; 28(5):307-10. PubMed ID: 8610057
[TBL] [Abstract][Full Text] [Related]
20. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
Hedlund PO; Damber JE; Hagerman I; Haukaas S; Henriksson P; Iversen P; Johansson R; Klarskov P; Lundbeck F; Rasmussen F; Varenhorst E; Viitanen J;
Scand J Urol Nephrol; 2008; 42(3):220-9. PubMed ID: 18432528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
